Plasma suPAR level in patients with multiple myeloma.
- Author:
Wei WANG
1
;
Hong-Yi WANG
;
Zhong-Guang CUI
;
Jing WANG
Author Information
1. Department of Hematology, The Affiliated Hospital of Qingdao University Medical College, Qingdao 266003, Shandong Province, China.
- Publication Type:Journal Article
- MeSH:
Aged;
Enzyme-Linked Immunosorbent Assay;
Female;
Humans;
Male;
Middle Aged;
Multiple Myeloma;
blood;
classification;
Prognosis;
Receptors, Urokinase Plasminogen Activator;
blood;
Solubility
- From:
Journal of Experimental Hematology
2008;16(1):197-199
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the changes of plasma suPAR level in patients with multiple myeloma, ELISA was used to detect plasma suPAR level, and routine examination was performed for other clinical indexes in 26 multiple myeloma patients. The results showed that plasma suPAR level in patients was 4.31+/-1.67 ng/ml, which was obviously higher than that in control group (1.87+/-0.27 ng/ml) (p<0.01). Plasma suPAR level in IgM subtype patients was 6.18+/-3.61 ng/ml, which was highest among all the subtypes; the plasma suPAR levels in non-secretion subtype, IgG and IgA subtype were 4.43+/-1.55 ng/ml, 4.00+/-0.95 ng/ml and 3.50+/-1.60 ng/ml respectively. The plasma suPAR levels in all subtypes were higher than that in control group, but there was no differences between these subtypes. SuPAR level was correlated with the blood sedimentation rate, creatinine level and hemoglobin level, plasma cell ratio and M protein level. It is concluded that the change of plasma suPAR level in multiple myeloma contributes to predict the development and prognosis of the disease.
